Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176813 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00176813 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 5 participants.
The verdict
NCT00176813, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will examine an investigational (experimental) treatment using gemcitabine, cisplatin, and celecoxib. Preliminary studies have shown that this experimental treatment may be effective in reducing the size of cancerous tumors and/or preventing further tumor growth. This is a phase II clinical trial studying the reactions of the patient's body and their tumor to the combination of gemcitabine, cisplatin, and celecoxib. The purpose of this study is to see if the tumor responds to this treatment and to determine how long the response lasts. This study will also look at what kind of side effects this experimental treatment causes and see how often these side effects occur. Blood levels of celecoxib will be measured to find out how this treatment affects factors (proteins) involved in new blood vessel formation and tumor growth (angiogenesis).
Interventions
- DRUG Cisplatin
- DRUG Celecoxib
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176813
The ClinicalTrials.gov registry entry for NCT00176813 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00176813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176813 about?
NCT00176813 is a clinical study titled "Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer". This study will examine an investigational (experimental) treatment using gemcitabine, cisplatin, and celecoxib. Preliminary studies have shown that this experimental treatment may be effective in reducing the size of cancerous tumors and/or preventing further tumor growth. This is a phase II clini...
What is the current status of trial NCT00176813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2003-03. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00176813?
The interventions under investigation include: Cisplatin (DRUG), Celecoxib (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00176813?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.